medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in adult and pediatric patients aged 1 year and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).

Testing new substances in animals is a regulatory cornerstone of drug development. At the same time, the development of animal free testing methods is progressing. In this context the pharmaceutical company medac and the start-up chiron biotechnology are working together on the further development and establishment of animal free testing methods for the pharmaceutical industry.

medac group, a reliable partner in contract development and manufacturing, is pleased to report a series of productive and insightful meetings with both current and potential business partners during this year’s CPHI Congress in Milan, held from 8–10 October 2024.

At this year's EULAR congress, medac will present in addition to its symposium on the topic of optimizing methotrexate, its new Pen to an international audience for the first time. Visitors of the booth will have the opportunity to experience the new features at first hand and find out all the latest news about the modern device.

The highly anticipated hybrid symposium on "Optimizing Outcomes for Patients With NMIBC - Challenges and Recent Developments in Clinical Practice" sponsored by medac, was a complete success.